Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an announcement.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Hong Kong-listed pharmaceutical company, announced that its H shares have been included in the list of eligible securities under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect, effective 24 December 2025. The inclusion will allow eligible mainland Chinese investors to directly trade the company’s H shares through the Shanghai and Shenzhen stock exchanges, a move expected to broaden its investor base and potentially boost trading liquidity, with implications for greater market visibility and enhanced access to cross-border capital.
The most recent analyst rating on (HK:2315) stock is a Hold with a HK$32.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a Hong Kong-listed pharmaceutical company incorporated in the PRC, with its H shares traded on the Stock Exchange of Hong Kong under stock code 2315. The company operates in the biopharmaceutical sector, focusing on drug research and development and related pharmaceutical activities for investors in both mainland China and Hong Kong.
Average Trading Volume: 553,482
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.18B
For a thorough assessment of 2315 stock, go to TipRanks’ Stock Analysis page.